April 29, 2017
Silver Nanoparticles and Postsurgical Wound Treatment
Silver nanoparticles have demonstrated marked antibacterial activity against multi-drug resistant bacteria commonly found in infected postsurgical wounds in humans.
By JoAnna Pendergrass, DVM

Postsurgical wound infections affect 15% to 60% of surgical patients. These wounds are frequently nosocomial and can have serious financial and health consequences. The bacteria most commonly found in postsurgical wounds—Staphylococcus aureus, Pseudomonas aeruginosa, coagulase-negative staphylococci (CoNS)—demonstrate multi-drug resistance, making wound treatment difficult.
Ag-NPs have strong antimicrobial activity at low concentrations with minimal toxicity. Researchers have begun to explore “green,” chemical-free methods to synthesize Ag-NPs. One such method is the use of leaf extracts, such as that from the shrub Corchorus capsularis. C. capsularis has many clinical uses (laxative, appetite stimulant) and can act as a reducing and stabilizing agent for Ag-NP synthesis.
For the current study, researchers synthesized Ag-NPs from a C. capsularis leaf extract and used advanced imaging techniques to analyze the Ag-NPs’ size, morphology, and crystal structure. They also collected wound swab samples from patients with clinically evident postsurgical wound infections; swabs underwent testing to determine gram negativity or positivity. Researchers then performed a series of tests to evaluate the Ag-NPs’ antibacterial activity against the 3 bacterial isolates (S. aureus, P. aeruginosa, CoNS) as well as cytotoxicity.
Study Results
Ag-NP Structural Characteristics
Using UV-visible spectroscopy, researchers demonstrated Ag-NP stability for up to 1 month at room temperature. Transmission electron microscopy indicated that the Ag-NPs were elliptical and spheroidal; using a histogram, researchers calculated a mean Ag-NP size of 20.5 nm. Other imaging techniques, including X-ray diffraction, revealed the Ag-NPs’ highly crystalline structure with minimal crystal asymmetry.
Ag-NP Antibacterial Activity
Researchers performed a disk diffusion assay, which demonstrated that increased Ag-NP concentrations linearly increased diameters of the zones of inhibition for each of the bacterial isolates. Mean zone of inhibition diameters were generally similar among the isolates at the highest Ag-NP concentration used (60 µg/mL). Notably, Ag-NP activity was favorable to that of gentamicin.
Another assay was performed by treating about 100 colony-forming units (CFU) of bacterial isolates with increasing Ag-NP concentrations, up to 100 µg/mL. The number of CFUs dropped markedly with higher Ag-NP concentrations, particularly for S. aureus and CoNS. Researchers observed that reduction of CFU numbers was notable even at the lowest Ag-NP concentrations.
Bacterial growth kinetics were also measured. At 3-hour intervals up to 24 hours, bacterial growth decreased over time and with increasing Ag-NP concentration.
To explain this antibacterial activity, researchers described how Ag-NPs penetrate the bacterial cell wall and release silver ions, which generate reactive oxygen species; the reactive oxygen species likely play a major role in Ag-NP antibacterial activity, which includes disrupting both cell membrane integrity and important cellular functions, ultimately resulting in cell death.
Ag-NP Cytotoxicity
At a range of concentrations up to 200 µg/mL, Ag-NPs demonstrated minimal cytotoxicity in mouse embryo fibroblast cells. In fact, toxicity remained undetectable at each Ag-NP concentration until the last time point (72 hours), at which toxicity was detected at the 3 highest concentrations.
Conclusions
Study results indicate the potential clinical usefulness of Ag-NP for treating postsurgical skin wounds infected with multi-drug resistant bacteria. In addition, the authors noted, Ag-NPs could be used to produce wound-healing bandages.
Dr. JoAnna Pendergrass received her Doctor of Veterinary Medicine degree from the Virginia-Maryland College of Veterinary Medicine. Following veterinary school, she completed a postdoctoral fellowship at Emory University’s Yerkes National Primate Research Center. Dr. Pendergrass is the founder and owner of JPen Communications, a medical communications company.
Sign up to receive the latest news in veterinary medicine.